Source comparison
CJC-1295 Safety Studies: Comparison to Other GH Secretagogues
Understanding where CJC-1295 sits relative to other growth hormone secretagogues provides context for interpreting its safety profile. The table below compares key safety and tolerability data across four commonly researched compounds. CJC-1295 GHRH analog wit
This comparison does not assign a generated winner or score.
- Understanding where CJC-1295 sits relative to other growth hormone secretagogues provides context for interpreting its safety profile. The table below compares key safety and tolerability data across four commonly researched compounds.
- CJC-1295
- GHRH analog with DAC modification
- Phase I/II
- Injection site reactions (30%), transient flushing (12%)
- 45–75%
- 28 days
- Well-tolerated short-term, but long-term human data does not exist. Discontinued before Phase III
- Ipamorelin
- Ghrelin receptor agonist
- Phase II
- Nausea (8%), headache (5%)
- 20–35%
- 90 days
- Lower IGF-1 response, better GI tolerability, but still lacks multi-year outcome data
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- Increased appetite (40%), transient edema (15%)
- 30–60%
- 2 years
- Only GH secretagogue with multi-year human trial data. Showed increased fasting glucose in elderly subjects
- Tesamorelin
- GHRH analog (no DAC)
- FDA-approved
- Injection site reactions (35%), arthralgia (12%)
- 25–50%
- 26 weeks (approval trial)
- FDA-approved for HIV-associated lipodystrophy. Most robust human safety dataset of any GHRH analog
- CJC-1295 sits between Tesamorelin and MK-677 in terms of IGF-1 response magnitude, but its lack of progression to Phase III means it has the sparsest long-term safety data of the group. MK-677 is the only compound in this comparison with published human trial data extending beyond one year. The 2-year elderly cohort study published in the Journal of Clinical Endocrinology & Metabolism found increased fasting glucose and modest increases in HbA1c, raising questions about metabolic risk with chronic GH elevation. Whether CJC-1295 would produce similar effects remains speculative.